- Home
- LQDA vs OCUL Comparison
LQDA vs OCUL Comparison
Compare LQDA & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- OCUL
- Stock Information
- Founded
- LQDA 2004
- OCUL 2006
- Country
- LQDA United States
- OCUL United States
- Employees
- LQDA N/A
- OCUL N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- LQDA Health Care
- OCUL Health Care
- Exchange
- LQDA Nasdaq
- OCUL Nasdaq
- Market Cap
- LQDA 1.7B
- OCUL 1.8B
- IPO Year
- LQDA 2018
- OCUL 2014
- Fundamental
- Price
- LQDA $25.95
- OCUL $12.62
- Analyst Decision
- LQDA Strong Buy
- OCUL Strong Buy
- Analyst Count
- LQDA 10
- OCUL 7
- Target Price
- LQDA $31.40
- OCUL $17.17
- AVG Volume (30 Days)
- LQDA 3.4M
- OCUL 2.0M
- Earning Date
- LQDA 08-12-2025
- OCUL 08-05-2025
- Dividend Yield
- LQDA N/A
- OCUL N/A
- EPS Growth
- LQDA N/A
- OCUL N/A
- EPS
- LQDA N/A
- OCUL N/A
- Revenue
- LQDA $19,322,000.00
- OCUL $56,664,000.00
- Revenue This Year
- LQDA $190.73
- OCUL N/A
- Revenue Next Year
- LQDA $421.01
- OCUL $20.85
- P/E Ratio
- LQDA N/A
- OCUL N/A
- Revenue Growth
- LQDA 30.20
- OCUL N/A
- 52 Week Low
- LQDA $8.26
- OCUL $5.79
- 52 Week High
- LQDA $26.65
- OCUL $12.91
- Technical
- Relative Strength Index (RSI)
- LQDA 79.56
- OCUL 67.49
- Support Level
- LQDA $19.02
- OCUL $12.14
- Resistance Level
- LQDA $26.65
- OCUL $12.91
- Average True Range (ATR)
- LQDA 1.53
- OCUL 0.65
- MACD
- LQDA 0.64
- OCUL -0.05
- Stochastic Oscillator
- LQDA 92.88
- OCUL 87.55
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.